Advances in targeted therapies IX
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis
New therapies for sepsis: focus on the interleukin (IL)12 family member IL27
Interpreting measurements of physical function in clinical trials
Thoughts on health economics in rheumatoid arthritis
Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean?
Joint remodelling in inflammatory disease
Amplifying elements of arthritis and joint destruction
Schnurri-3 is an essential regulator of osteoblast function and adult bone mass
α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs
Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility
Disease activity assessment in SLE: do we have the right instruments?
Systemic lupus erythematosus: new molecular targets
Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy
Update on toll-like receptor-directed therapies for human disease
Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue
Interplay between pathogenic Th17 and regulatory T cells
Regulatory T cells and toll-like receptors: regulating the regulators